Rubicon Organics Inc ROMJ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ROMJ is a good fit for your portfolio.
News
-
Rubicon Organics Reports Q1 2024 Financial Results
-
Rubicon Organic Launches 1964 Supply Co.™ Full Spectrum Extracts (FSE) Vapes
-
Rubicon Organics to Report Q1 2024 Results
-
Rubicon Organics Reports 2023 Financial Results
-
Rubicon Organics to Report Q4 2023 Results
-
Rubicon Organics Brings 1964 Supply Co. Cannabis-Infused Poutine Sauce to Quebec
Trading Information
- Previous Close Price
- CAD 0.55
- Day Range
- CAD 0.39–0.45
- 52-Week Range
- CAD 0.33–0.64
- Bid/Ask
- CAD 0.38 / CAD 0.40
- Market Cap
- CAD 21.63 Mil
- Volume/Avg
- 160,347 / 27,733
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.54
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Rubicon Organics Inc is engaged in the business of the production and sale of cannabis in Canada. The Company produces and processes organic cannabis at its wholly-owned, federally licensed facility in Delta, British Columbia which it sells under its wholly owned and other licensed brands such as Lab Theory, Wildflower, Homestead Cannabis Supply, 1964 Supply Co, and Simply Bare Organic.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 167
- Website
- https://www.rubiconorganics.com
Valuation
|
Metric
|
ROMJ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.59 |
Price/Sales | 0.54 |
Price/Cash Flow | 5.85 |
Price/Earnings
ROMJ
Financial Strength
|
Metric
|
ROMJ
|
|---|---|
Quick Ratio | 1.73 |
Current Ratio | 3.48 |
Interest Coverage | −4.07 |
Quick Ratio
ROMJ
Profitability
|
Metric
|
ROMJ
|
|---|---|
Return on Assets (Normalized) | −7.01% |
Return on Equity (Normalized) | −12.90% |
Return on Invested Capital (Normalized) | −5.78% |
Return on Assets
ROMJ
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Lxlkdqxhh | Yrylrg | $79.9 Bil | |
ZTS
| Zoetis Inc Class A | Cbjrlrnqn | Qdwf | $79.3 Bil | |
HLN
| Haleon PLC ADR | Xfmdzrtf | Lykj | $38.1 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Jcnmqszv | Brds | $18.9 Bil | |
VTRS
| Viatris Inc | Lyhjyrjf | Xvz | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Lxnspxrc | Vsttr | $11.7 Bil | |
CTLT
| Catalent Inc | Zmhbpbhx | Hrxgky | $10.0 Bil | |
CURLF
| Curaleaf Holdings Inc | Njwykkm | Llpl | $4.2 Bil | |
PRGO
| Perrigo Co PLC | Vrdkvjzrl | Bvmvv | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Rmqkgzbvt | Dclrnv | $3.2 Bil |